63 articles
Engineered bacterial vesicles injected into tumors activated whole-body immune responses against melanoma, colon, and breast cancer, offering a safer.
Colorectal cancer rates in adults under 50 have risen 63% since 1988; a new blood test could screen patients as young as 18.
Scientists engineered CAR-T cells that attack both tumor cells and the immune barriers protecting them, targeting PD-L1 to dismantle cancer's defenses.
A large NHS study found a multi-cancer blood test missed its main goal, yet still caught 16% more early-stage cancers and cut emergency diagnoses by 25%.
A new colorectal cancer drug combination improved survival to 10.9 months versus 9.4, but showed no significant benefit for patients without liver.
Personalized melanoma vaccines paired with immunotherapy are pushing survival rates from below 10% to nearly 40%, but equitable access remains a critical.
Breast cancer survivors face 17% higher cancer risk, but a new study finds annual multicancer blood tests could prevent hundreds of late-stage diagnoses.
Scientists found that blocking a protein called DHHC3 in melanoma cells triggers a powerful immune attack, shrinking tumors in animal models.
Daraxonrasib targets KRAS, mutated in 90% of pancreatic cancers, offering new hope for patients who have exhausted standard treatments.
New breast cancer research shows 68% of early-stage patients may skip chemotherapy safely, while new drug combos extend metastatic survival by years.
You can get breast and cervical cancer screening without a doctor through self-referral programs, community clinics, and health departments.
New drug combination cuts prostate cancer progression risk by 52% while pre-surgery treatment boosts survival odds in breakthrough trials.
Immunotherapy for melanoma achieves 60% response rates but can cause life-threatening side effects requiring careful monitoring and specialist care.
New research shows PSMA-PET imaging detects hidden prostate cancer in 100% of patients even when PSA blood tests suggest excellent treatment response.
AI cuts breast cancer wait times from weeks to an hour, helping doctors fast-track diagnosis for high-risk women using mammogram screening.
Breast cancer screening guidelines conflict on when to start mammograms, but most experts agree: average-risk women should begin at age 40, annually.
Genetic testing beyond KRAS mutations now predicts colon cancer treatment response, with BRAF and 18q markers reshaping personalized therapy decisions.
Early breast cancer detection dramatically improves survival rates: doctors reveal key warning signs and screening tests every woman should know.
Rich countries will eliminate cervical cancer by 2048, but the gap with poorer nations could widen to 40 times higher rates without urgent investment.
A personalized melanoma vaccine plus immunotherapy cut cancer recurrence risk by 49% over five years, offering durable protection against skin cancer.
A personalized mRNA melanoma vaccine cut cancer recurrence risk by 49% in five-year trials, keeping nearly 69% of patients cancer-free.
Women should start breast cancer screening at 40 and can now self-collect cervical samples, making early detection more accessible than ever.
Colorectal cancer symptoms like blood in stool and bowel changes are often dismissed, but doctors say any persistent signs need immediate attention.
Melanoma patients' five-year survival odds jump from 29% to 91% as they stay cancer-free longer on immunotherapy, new research reveals.
Prostate cancer screening may benefit colorectal cancer survivors, but prior treatments complicate PSA tests and limit treatment options.
Skipping cancer screenings is the biggest mistake you can make, say three oncologists who warn most cancers show no symptoms until advanced.
PSA screening raises the odds of early-stage prostate cancer diagnosis by 52%, a new real-world analysis of nearly 8,000 patients shows.
Only 51% of Americans get annual cancer screenings, but 73% schedule them after learning early detection benefits could save their lives.
New colorectal cancer screening guidelines add blood tests and at-home stool options, giving the 1 in 3 unscreened adults more ways to get tested.
Researchers unveil combination therapies and engineered cell treatments to overcome melanoma immunotherapy resistance affecting many patients.
New immunotherapy approaches targeting CD8+ T cells show 67% response rates in hard-to-treat melanoma patients who failed checkpoint inhibitors.
Researchers identified a gene expression pattern that predicts which prostate cancer patients will benefit from immunotherapy combination treatment.
A novel breast cancer combination therapy shows early promise for high-risk HER2-negative patients in the I-SPY 2.2 trial results.
Researchers discover that ATM gene mutations in pancreatic cancer reprogram surrounding tissue, offering a precision medicine pathway for 17-25% of patients...
Simone Herbin-Canty's HER2+ breast cancer journey led to complete recovery and inspired Chemo Buddy, ensuring no patient faces treatment alone.
New research reveals that gut microbiome imbalances reduce immunotherapy effectiveness for skin cancer and other cancers by up to 70%, but targeted...
Women ages 40 to 74 should get mammograms every two years for average breast cancer risk, but those with family history may need earlier or more frequent...
About 1.5 million prostate biopsies occur annually in the US, but experts say most are unnecessary.
Ovarian cancer kills roughly 140,000 women yearly worldwide, yet receives far less attention than breast cancer.
Ovarian cancer kills 140,000 women yearly because it's rarely caught early. Unlike breast cancer screening, there's no reliable early detection test, making...
Researchers at OHSU found that B cells can settle permanently in tissues and neutralize cancer cells when trained with vaccines, offering a localized...
Nearly 50% of cancer deaths in the US are linked to modifiable risk factors like smoking, weight, and alcohol.
China's top hospitals now offer comprehensive cancer screening with advanced imaging technology at a fraction of Western costs, attracting international...
FDA approves pembrolizumab plus chemotherapy for platinum-resistant ovarian cancer, extending survival by 4.2 months in a landmark trial.
Researchers found that liver cells, not immune cells, are the real bottleneck in mRNA cancer vaccine effectiveness.
A renowned breast surgeon becomes the inaugural holder of an endowed chair dedicated to surgical excellence, positioning her research on genetic risk factors...
Tumor-associated macrophages sabotage cancer treatment in ovarian, cervical, and endometrial cancers by creating immunosuppressive barriers.
Opdivo, a checkpoint inhibitor immunotherapy, blocks cancer's ability to hide from immune cells, offering new hope for melanoma and other skin cancers.
New technologies combining artificial intelligence, MRI imaging, and biomarker testing are transforming prostate cancer screening to catch aggressive tumors...
A large clinical trial found that combining three cancer drugs didn't improve survival better than two drugs alone, challenging assumptions about combination...
